| Abstract |
Biologics like dupilumab have revolutionized the management of patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma (1-3). However, topical corticosteroids, such as intranasal (INCS) and inhaled (ICS) corticosteroids still play a fundamental role in the management of these conditions (4, 5). To this day, limited data is available on topical corticosteroids medication adherence combined with dupilumab in achieving CRSwNP and asthma symptom control. Considering the generally poor medication-adherence among chronic patients and the remarkable efficacy of dupilumab, we suspected low adherence to INCS and ICS (6-8). |
